Radio and PodcastLive Radio & Podcasts
Health
New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions
Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue i...
About This Episode
New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions is an episode from JAMA Medical News: Discussing timely topics in clinical medicine, biomedical sciences, public health, and health policy by American Medica...
Podcast
This episode belongs to JAMA Medical News: Discussing timely topics in clinical medicine, biomedical sciences, public health, and health policy.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jun 18, 2026, 22:49 long, audio available.
Related Episodes
Continue listening to more episodes from JAMA Medical News: Discussing timely topics in clinical medicine, biomedical sciences, public health, and health policy.
PMOS is the New PCOS
Jun 26, 2026 - 05:35
Why Exercise Still Matters in the GLP-1 Drug Era
Jun 18, 2026 - 04:57
The Search for a Fentanyl Vaccine
Jun 12, 2026 - 05:32
New Insights on HFpEF in Patients With Severe Obesity
Jun 5, 2026 - 04:48
Is There a Doctor on the Ship?
May 29, 2026 - 17:03
Ebola Outbreak Update
May 29, 2026 - 06:20
Bangladesh's New Measles Crisis
May 22, 2026 - 04:51